scholarly journals Plasmodium falciparum: new molecular targets with potential for antimalarial drug development

2009 ◽  
Vol 7 (9) ◽  
pp. 1087-1098 ◽  
Author(s):  
Donald L Gardiner ◽  
Tina S Skinner-Adams ◽  
Christopher L Brown ◽  
Katherine T Andrews ◽  
Colin M Stack ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Drug Development ◽  
Antimalarial Drug ◽  
Molecular Targets ◽  
New Molecular Targets

Antimalarial Drugs as Inspiration for Herbicides

2020 ◽  
Vol 31 (5) ◽  
pp. 216-220
Author(s):  
Joshua S. Mylne ◽  
Keith A. Stubbs
Keyword(s):  
Plasmodium Falciparum ◽  
Drug Development ◽  
Herbicide Resistance ◽  
Antimalarial Drug ◽  
Antimalarial Drugs ◽  
Malarial Parasite ◽  
Malaria Research ◽  
Close Relationship ◽  
Popular Subject ◽  
Drug Leads

In addition to good stewardship, the unabated rise in herbicide resistance and dearth of truly new herbicides demands that new molecules be found. Over 30 years ago, a chloroplast-like organelle was found in the malarial parasite Plasmodium falciparum and herbicides demonstrated a close relationship existed to plants. Recently this idea was turned on its head by exploiting the boom in malaria research to search for new herbicide chemistry and it provided interesting starting points for development. The merit of such an approach is underlined by tetflupyrolimet, the first truly novel herbicide in 30 years, and whose target has been a popular subject for antimalarial drug development for 15 years. Which other antimalarial targets, drugs and drug leads might reach across the parasite-plant divide to inspire new herbicides?

Novel Molecular Targets for Antimalarial Drug Development

2008 ◽  
Vol 71 (4) ◽  
pp. 287-297 ◽  
Author(s):  
Nitendra K. Sahu ◽  
Sanjeev Sahu ◽  
Dharm Veer Kohli
Keyword(s):  
Drug Development ◽  
Antimalarial Drug ◽  
Molecular Targets

Novel inhibitors of the Plasmodium falciparum electron transport chain

Parasitology ◽  
2014 ◽  
Vol 141 (1) ◽  
pp. 50-65 ◽  
Author(s):  
P. A. STOCKS ◽  
V. BARTON ◽  
T. ANTOINE ◽  
G. A. BIAGINI ◽  
S. A. WARD ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Electron Transport ◽  
Drug Development ◽  
Antimalarial Drug ◽  
Electron Transport Chain ◽  
Type Ii ◽  
Dihydroorotate Dehydrogenase ◽  
Cytochrome Bc ◽  
Transport Chain ◽  
Promising Area

SUMMARYDue to an increased need for new antimalarial chemotherapies that show potency against Plasmodium falciparum, researchers are targeting new processes within the parasite in an effort to circumvent or delay the onset of drug resistance. One such promising area for antimalarial drug development has been the parasite mitochondrial electron transport chain (ETC). Efforts have been focused on targeting key processes along the parasite ETC specifically the dihydroorotate dehydrogenase (DHOD) enzyme, the cytochrome bc1 enzyme and the NADH type II oxidoreductase (PfNDH2) pathway. This review summarizes the most recent efforts in antimalarial drug development reported in the literature and describes the evolution of these compounds.

scholarly journals Atovaquone Tolerance in Plasmodium falciparum Parasites Selected for High-Level Resistance to a Dihydroorotate Dehydrogenase Inhibitor

2014 ◽  
Vol 59 (1) ◽  
pp. 686-689 ◽  
Author(s):  
Jennifer L. Guler ◽  
John White ◽  
Margaret A. Phillips ◽  
Pradipsinh K. Rathod
Keyword(s):  
Plasmodium Falciparum ◽  
Drug Development ◽  
Cross Talk ◽  
Antimalarial Drug ◽  
Pyrimidine Biosynthesis ◽  
Dihydroorotate Dehydrogenase ◽  
Development Programs ◽  
Genetic Cross ◽  
High Level ◽  
Level Resistance

ABSTRACTAtovaquone is a component of Malarone, a widely prescribed antimalarial combination, that targets malaria respiration. Here we show that parasites with high-level resistance to an inhibitor of dihydroorotate dehydrogenase demonstrate unexpected atovaquone tolerance. Fortunately, the tolerance is diminished with proguanil, the second partner in Malarone. It is important to understand such “genetic cross talk” between respiration and pyrimidine biosynthesis since many antimalarial drug development programs target these two seemingly independent pathways.

Antimalarial Drug Targets and Drugs Targeting Dolichol Metabolic Pathway of Plasmodium falciparum

2014 ◽  
Vol 15 (4) ◽  
pp. 374-409 ◽  
Author(s):  
Tabish Qidwai ◽  
Avantika Priya ◽  
Nihal Khan ◽  
Himanshu Tripathi ◽  
Feroz Khan ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Metabolic Pathway ◽  
Antimalarial Drug ◽  
Drug Targets

Old Drugs with New Tricks; Paradigm in Drug Development Pipeline for Alzheimer’s Disease

2020 ◽  
Vol 20 ◽  
Author(s):  
Tanay Dalvi ◽  
Bhaskar Dewangan ◽  
Rudradip Das ◽  
Jyoti Rani ◽  
Suchita Dattatray Shinde ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Development ◽  
Molecular Targets ◽  
Drug Repurposing ◽  
Phase Iii ◽  
Complex Nature ◽  
New Drug ◽  
Development Pipeline ◽  
Old Drugs

: The most common reason behind dementia is Alzheimer’s disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.

Sign in / Sign up

Export Citation Format

Share Document